Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Primary thyroid lymphoma.

S M Ansell1, C S Grant, T M Habermann

  • 1Department of Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA.

Seminars in Oncology
|June 22, 1999
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Report of consensus panel 7 from the 11th international workshop on Waldenström macroglobulinemia on priorities for novel clinical trials.

Seminars in hematology·2023
Same author

Lenalidomide plus R-CHOP21 in newly diagnosed diffuse large B-cell lymphoma (DLBCL): long-term follow-up results from a combined analysis from two phase 2 trials.

Blood cancer journal·2018
Same author

Reply to the letter to the editor 'Progression-free survival at 24 months (PFS24) and subsequent outcome for patients with diffuse large B-cell lymphoma (DLBCL) in the real-world setting' by van der Galiën et al.

Annals of oncology : official journal of the European Society for Medical Oncology·2018
Same author

Progression-free survival at 24 months (PFS24) and subsequent outcome for patients with diffuse large B-cell lymphoma (DLBCL) enrolled on randomized clinical trials.

Annals of oncology : official journal of the European Society for Medical Oncology·2018
Same author

Infusion of autograft natural killer cell/CD14<sup>+</sup>HLA-DR<sup>DIM</sup> cell ratio predicts survival in lymphoma post autologous stem cell transplantation.

Bone marrow transplantation·2017
Same author

A phase 1 trial of <sup>90</sup>Y-Zevalin radioimmunotherapy with autologous stem cell transplant for multiple myeloma.

Bone marrow transplantation·2017
Same journal

A systematic scoping review of cancer-related anemia treatment: Comparative trial outcomes, current guidelines, and future perspectives.

Seminars in oncology·2026
Same journal

Steroid-induced tumor lysis syndrome in solid tumors: A case report and review of the literature.

Seminars in oncology·2026
Same journal

PSMA PET/CT staging in intermediate-risk prostate cancer: Toward risk-adapted implementation.

Seminars in oncology·2026
Same journal

Angiogenesis and the corresponding antiangiogenic therapy in gastroenteropancreatic neuroendocrine neoplasms.

Seminars in oncology·2026
Same journal

Post-translational regulation of steroidogenesis and its clinical relevance in hormone responsive cancers.

Seminars in oncology·2026
Same journal

Physics-informed machine learning for tumor microenvironment-responsive nanomedicine: Recent updates.

Seminars in oncology·2026
See all related articles

Thyroid lymphoproliferative disorders require differentiation from benign conditions and cancer. Management strategies have advanced, focusing on therapies like radiation and chemotherapy rather than routine surgery.

Area of Science:

  • Endocrinology
  • Hematology
  • Pathology

Background:

  • Thyroid lymphoproliferative disorders present a diverse clinical and pathological spectrum.
  • Distinguishing these from benign thyroiditis and carcinoma is crucial for accurate diagnosis and treatment.
  • Clinical presentations vary, including neck masses, dysphagia, hoarseness, choking, or cold thyroid nodules.

Purpose of the Study:

  • To review the clinical and pathological spectrum of thyroid lymphoproliferative disorders.
  • To highlight advances in the clinical management and treatment of these conditions.
  • To emphasize the importance of accurate histopathologic interpretation and adequate tissue sampling.

Main Methods:

  • Review of clinical presentations and histopathologic findings of thyroid lymphoproliferative disorders.

Related Experiment Videos

  • Discussion of diagnostic challenges and the role of new pathological entities, such as mucosa-associated lymphoid tissue (MALT) lymphoma.
  • Analysis of current management strategies, including chemotherapy and radiation therapy.

    • Main Results:

    • Accurate histopathologic interpretation is essential for diagnosing thyroid lymphomas.
    • New pathological entities like MALT lymphoma have improved understanding of clinical course and management.
    • Surgical resection is not the primary management strategy; therapeutic approaches are tailored to specific lymphoma types.

    Conclusions:

    • Thyroid lymphoproliferative disorders necessitate careful differentiation from other thyroid pathologies.
    • Management has evolved, with non-surgical approaches like radiation and chemotherapy being central.
    • Specific treatment protocols, such as CHOP chemotherapy for diffuse large B-cell lymphoma, are established.